A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

University of Arizona Cancer Center, Tucson, Arizona, United States

University of California San Diego Moores Cancer Center, La Jolla, California, United States

Cedars-Sinai Medical Center, Los Angeles, California, United States

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States

Yale - New Haven Hospital, New Haven, Connecticut, United States

HealthPartners Cancer Research Center, Saint Paul, Minnesota, United States

Washington University School of Medicine, St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

Cleveland Clinic, Cleveland, Ohio, United States

Providence Cancer Institute, Portland, Oregon, United States

SCRI Oncology Partners, Nashville, Tennessee, United States

Texas Oncology, Dallas, Texas, United States

University of Texas Southwestern Medical Center, Dallas, Texas, United States

University Medical Center & Texas Tech Health Science Center, Lubbock, Texas, United States

Virginia Cancer Specialists, Fairfax, Virginia, United States

Swedish Medical Center, Seattle, Washington, United States

Fred Hutchinson Cancer Center, Seattle, Washington, United States

University of Wisconsin - Carbone Cancer Center, Madison, Wisconsin, United States